Intellia Therapeutics Inc buy Canaccord Genuity Group Inc.
Start price
16.06.26
/
50%
€11.80
Target price
16.06.27
€42.31
Performance (%)
-12.71%
Price
14.08.26
€10.30
Summary
This prediction is currently active. The prediction for Intellia Therapeutics Inc disappoints with a performance of -12.71%. This prediction currently runs until 16.06.27. The prediction end date can be changed by Canaccord_Genuity_Gr at any time. Canaccord_Genuity_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Intellia Therapeutics Inc | -0.387% | -0.387% |
| iShares Core DAX® | 0,44 % | 5,64 % |
| iShares Nasdaq 100 | 1,06 % | 0,28 % |
| iShares Nikkei 225® | 1,77 % | 0,41 % |
| iShares S&P 500 | 0,37 % | 1,92 % |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $49.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Canaccord_Genuity_Gr for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€11.66
28.04.26
28.04.26
€49.51
28.04.27
28.04.27
-11.66%
14.08.26
14.08.26
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€11.99
03.03.26
03.03.26
€41.04
03.03.27
03.03.27
-14.06%
14.08.26
14.08.26
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€33.50
13.04.23
13.04.23
€59.72
13.04.24
13.04.24
-29.85%
14.04.24
14.04.24